Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010)

Diagnostic Microbiology and Infectious Disease

Volumn 75, Issue 1, 2013, Pages 86-88

  Farrell, David J ^a   Flamm, Robert K ^a   Jones, Ronald N ^a   Sader, Helio S ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Anti methicillin resistant; Cephalosporin; Haemophilus influenzae; Moraxella catarrhalis; Staphylococcus aureus; Streptococcus pneumoniae

Indexed keywords

AMPICILLIN; BETA LACTAMASE; CEFTAROLINE; CEFTRIAXONE; CEFUROXIME; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; PENICILLIN G; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; COMMUNITY ACQUIRED RESPIRATORY TRACT INFECTION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG POTENCY; EUROPE; HAEMOPHILUS INFLUENZAE; ISRAEL; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; TURKEY (REPUBLIC);

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; EUROPE; HUMANS; MICROBIAL SENSITIVITY TESTS; RESPIRATORY TRACT INFECTIONS;

EID: 84870765129     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.06.005     Document Type: Article

References (11)

1. Biek D., Critchley I.A., Riccobene T.A., Thye D.A. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity. J Antimicrob Chemother 2010, 65(Suppl. 4):iv9-iv16.
2. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - ninth edition, M07-A9 2012, CLSI, Wayne, PA.
3. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 23rd informational supplement (M100-S23) 2013, CLSI, Wayne, PA.
4. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0 Available online:, European Committee on Antimicrobial Susceptibility Testing 2013. http://www.eucast.org/clinical_breakpoints/.
5. Fenoll A., Aguilar L., Robledo O., Gimenez M.J., Granizo J.J., Biek D., et al. In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime. Antimicrob Agents Chemother 2008, 52:4209-4210.
6. File T.M., Low D.E., Eckburg P.B., Talbot G.H., Friedland H.D., Lee J., et al. FOCUS 1: A randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011, 66(Suppl. 3):iii19-iii32.
7. Jones R.N., Farrell D.J., Mendes R.E., Sader H.S. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. J Antimicrob Chemother 2011, 66(Suppl. 3):iii69-iii80.
8. Jones R.N., Jacobs M.R., Sader H.S. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int J Antimicrob Agents 2010, 36:197-204.
9. Low D.E., File T.M., Eckburg P.B., Talbot G.H., David Friedland H., Lee J., et al. FOCUS 2: A randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011, 66(Suppl. 3):iii33-iii44.
10. Morrissey I., Leakey A. Activity of ceftaroline against serotyped Streptococcus pneumoniae isolates from Europe and South Africa associated with community-acquired bacterial pneumonia (2007-08). J Antimicrob Chemother 2012, 67:1408-1412.
11. Teflaro Package Insert. New York City, NY Available online:, Accessed April 2012. http://www.frx.com/pi/Teflaro_pi.pdf.